

Selected Publications

McNeil BJ, Adelstein SJ. Measures of clinical efficacy. The value of case finding in hypertensive renovascular disease. *N Engl J Med* 1975; 293(5):221-6

Bloomer WD, Adelstein SJ. 5-125I-iododeoxyuridine as prototype for radionuclide therapy with Auger emitters. *Nature* 1977; 265(5595):620-1

Chan PC, Lisco E, Lisco H, Adelstein SJ. The radiotoxicity of iodine-125 in mammalian cells II. A comparative study on cell survival and cytogenetic responses to 125IUdR, 131TUdR, and 3HTdR. *Radiat Res* 1976; 67(2):332-43

Mee LK, Adelstein SJ. Predominance of core histones in formation of DNA--protein crosslinks in gamma-irradiated chromatin. *Proc Natl Acad Sci U S A* 1981; 78(4):2194-8

Bloomer WD, McLaughlin WH, Neirinckx RD, Adelstein SJ, Gordon PR, Ruth TJ, Wolf AP. Astatine-211--tellurium radiocolloid cures experimental malignant ascites. *Science* 1981; 212(4492):340-1

LeMotte PK, Adelstein SJ, Little JB. Malignant transformation induced by incorporated radionuclides in BALB/3T3 mouse embryo fibroblasts. *Proc Natl Acad Sci U S A* 1982; 79(24):7763-7

. Adelstein SJ. Uncertainty and relative risks of radiation exposure. *JAMA* 1987; 258(5):655-7

Macklis RM, Kinsey BM, Kassis AI, Ferrara JL, Atcher RW, Hines JJ, Coleman CN, Adelstein SJ, Burakoff SJ. Radioimmunotherapy with alpha-particle-emitting immunoconjugates. *Science* 1988; 240(4855):1024-6

Kassis AI, Van den Abbeele AD, Wen PY, Baranowska-Kortylewicz J, Aaronson RA, DeSisto WC, Lampson LA, Black PM, Adelstein SJ. Specific uptake of the auger electron-emitting thymidine analogue 5-[123I/125I]iodo-2'-deoxyuridine in rat brain tumors: diagnostic and therapeutic implications in humans. *Cancer Res* 1990; 50(16):5199-203

Adelstein SJ. Merrill C. Sosman Lecture. The Auger process: a therapeutic promise? *AJR Am J Roentgenol* 1993; 160(4):707-13

Tosteson DC, Adelstein SJ, Carver ST, Eds. *New Pathways to Medical Education: Learning to Learn at Harvard Medical School*. Harvard University Press, Cambridge MA 1994.

Adelstein SJ. The 2000 NCRP Lauriston S. Taylor lecture--administered radioactivity: unde venimus quoque imus. National Council on Radiation Protection and Measurements. Health Phys 2001; 80(4):317-24

Adelstein SJ, Green AJ, Howell RW, Humm JL, Lechner PK, O'Donoghue JA, Strand SE, Wessels BW. Absorbed dose specification in nuclear medicine. J of the ICRU (Report 67) 2002; 2(1): 1-110

Xue LY, Butler NJ, Makrigrigios GM, Adelstein SJ, Kassis AI. Bystander effect produced by radiolabeled tumor cells in vivo. Proc Natl Acad Sci U S A 2002; 99(21):13765-70

Britz-Cunningham SH, Adelstein SJ. Molecular targeting with radionuclides: state of the science. J Nucl Med 2003; 44(12):1945-61

Adelstein SJ, Kassis AI, Bodei L, Mariani G. Radiotoxicity of iodine-125 and other Auger-electron emitting radionuclides: Background to therapy. Cancer Therapy & Radiopharmaceuticals 2003; 18(6):861-877.

Adelstein SJ, Fry RJ, Little JB, Sinclair WK. A scientific, moral and diplomatic misstep. Radiat Res 2004; 161(6):621

Urashima T, Wang K, Adelstein SJ, Kassis AI. Activation of diverse pathways to apoptosis by (125)IdUrd and gamma-photon exposure. Int J Radiat Biol 2004; 80(11-12):867-74